Key facts
- This page summarizes Grant Pickering's Form 4 filing for Vaxcyte, Inc. (PCVX).
- 9 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2024, 16:17.
Grant Pickering - 23 Feb 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- PCVX
- Reported as of
- 23 Feb 2024
- Net transaction value
- -$3,433,556
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2024, 16:17:31 UTC
- Prior SEC filing
- 31 Jan 2024
- Next SEC filing
- 04 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron A. Metzger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Grant Pickering filed Form 4 for Vaxcyte, Inc. (PCVX) on 27 Feb 2024.
Change
- Previous filing in this sequence was filed on 31 Jan 2024.
- Current net transaction value: -$3,433,556.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCVX
transaction
Common Stock
Options Exercise
- Transaction value
- $26,850
- Shares
- +15,000
- Change %
- +4%
- Price
- $1.79*
- Shares after
- 390,814
- Date
- 23 Feb 2024
- Ownership
- Direct
PCVX
transaction
Common Stock
Sale
- Transaction value
- $177,063
- Shares
- -2,356
- Change %
- -0.6%
- Price
- $75.15
- Shares after
- 388,458
- Date
- 23 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
PCVX
transaction
Common Stock
Sale
- Transaction value
- $530,215
- Shares
- -6,980
- Change %
- -1.8%
- Price
- $75.96
- Shares after
- 381,478
- Date
- 23 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F3
PCVX
transaction
Common Stock
Sale
- Transaction value
- $426,699
- Shares
- -5,545
- Change %
- -1.5%
- Price
- $76.95
- Shares after
- 375,933
- Date
- 23 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F4
PCVX
transaction
Common Stock
Sale
- Transaction value
- $9,230
- Shares
- -119
- Change %
- -0.03%
- Price
- $77.56
- Shares after
- 375,814
- Date
- 23 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
PCVX
transaction
Common Stock
Options Exercise
- Transaction value
- $53,700
- Shares
- +30,000
- Change %
- +8%
- Price
- $1.79*
- Shares after
- 405,814
- Date
- 26 Feb 2024
- Ownership
- Direct
PCVX
transaction
Common Stock
Sale
- Transaction value
- $2,370,900
- Shares
- -30,000
- Change %
- -7.4%
- Price
- $79.03
- Shares after
- 375,814
- Date
- 26 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F5
PCVX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 149,978
- Date
- 23 Feb 2024
- Ownership
- By Children's Trust
- Footnotes
- F6
PCVX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 149,978
- Date
- 23 Feb 2024
- Ownership
- By Children's Trust
- Footnotes
- F7
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PCVX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -15,000
- Change %
- -20%
- Price
- $0.000000
- Shares after
- 60,225
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $1.79
- Footnotes
- F8
PCVX
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -30,000
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 30,225
- Date
- 26 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $1.79
- Footnotes
- F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 8 footnotes
Footnote F1
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023.
Footnote F2
The price reported is a weighted-average price. The shares were sold at prices ranging from $74.45 to $75.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F3
The price reported is a weighted-average price. The shares were sold at prices ranging from $75.545 to $76.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F4
The price reported is a weighted-average price. The shares were sold at prices ranging from $76.54 to $77.475. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F5
The price reported is a weighted-average price. The shares were sold at prices ranging from $79.03 to $79.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F6
Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Footnote F7
Shares are held directly by a trust for the benefit of the Reporting Person's son.
Footnote F8
Stock Option is fully vested and exercisable.